-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Health
Latest From Health
The Ethics of the Market Access Debate
At the core of the market access conversation lies the question of value. How much do we value two years added to the end of an 80-year-old’s life? How do we put a dollar amount on a medicine that prevents a rare disease patient, who may only live to age 20 regardless of receiving treatment, from losing her ability to walk? How can we define metrics to measure the cost of a child with a Read More >
Alzheimer’s Disease “Robs You of Everything”
George Hendrick and his wife, Mary Lee, experienced the typical highs and lows of parenthood as they raised nine children in New Lenox, a south suburb of Chicago. After the couple’s nest was nearly empty, in what was supposed to be their golden years, George was told he had memory and thinking problems, and later, Alzheimer’s disease. George’s long tenure as a Will County police officer was cut short. He could no longer carry a gun, and Read More >
Biomedical R&D in the 21st Century
Reflecting back upon my career, I recognize the importance academic-industry research partnerships played in shaping my philosophy as a scientist and research leader. Something deeply fulfilling happens when basic and applied scientists ally, and our individual passion to make a difference in the life of a patient merges into a community effort. We are moving ever closer to solving some of the toughest biomedical challenges of our time. But this is also an era of Read More >
#BIO 2013: Open Innovation and Biopharmaceutical R&D
In these changing times, the concept of Open Innovation is one that we at AstraZeneca have fully embraced. By sharing new ideas and enabling scientific innovation to cross boundaries between companies, academia, government and non-profit organizations, we can accelerate new ideas into innovative medicines. An Open Innovation discussion at BIO I will discuss the importance that AstraZeneca places on Open Innovation today at this year’s BIO International Convention. An interactive session will include a panel discussion and presentations Read More >
Q & A with Eli Lilly’s Eric Siemers
In October 2012, Eli Lilly and Company released results of its Expedition trials, two Phase 3, double-blind, placebo-controlled studies of the anti-amyloid antibody solanezumab, in patients with mild-to-moderate Alzheimer’s disease. Although cognitive decline was slowed in patients with early stage disease in one trial, and there were also positive signs from the other trial, those findings were not statistically significant. But a secondary analysis conducted independently by a panel of academic researchers pooled data from Read More >
